Active	Status	Sponsor type	Region	Phase	Filter
13 Active 2 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Dinner, Shira
NCT05289687: Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL	Recruiting	2	20	US	Daratumumab / Hyaluronidase Injection	Eastern Cooperative Oncology Group, Janssen, LP	T-cell Acute Lymphoblastic Leukemia	06/27	06/27
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL	Recruiting	1/2	225	Europe, Japan, US, RoW	Rapcabtagene autoleucel single agent, Ibrutinib	Novartis Pharmaceuticals	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma	06/27	05/28